Business Description
ProMIS Neurosciences Inc
NAICS : 325410
SIC : 3741
ISIN : CA74346M1095
Total Employee Number:
11Description
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.9 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 27.5 | |||||
3-Year EPS without NRI Growth Rate | 34 | |||||
3-Year FCF Growth Rate | 34.4 | |||||
3-Year Book Growth Rate | 47 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 38.31 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.75 | |||||
9-Day RSI | 59.03 | |||||
14-Day RSI | 53.8 | |||||
3-1 Month Momentum % | -13.46 | |||||
6-1 Month Momentum % | 61.03 | |||||
12-1 Month Momentum % | -9.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.92 | |||||
Quick Ratio | 9.92 | |||||
Cash Ratio | 9.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -84.4 | |||||
Shareholder Yield % | -72.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -261.24 | |||||
ROA % | -167.54 | |||||
ROIC % | -5183.25 | |||||
3-Year ROIIC % | -28943.1 | |||||
ROC (Joel Greenblatt) % | -1851.74 | |||||
ROCE % | -262.62 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.94 | |||||
Price-to-Tangible-Book | 1.94 | |||||
EV-to-EBIT | -1.32 | |||||
EV-to-Forward-EBIT | -0.59 | |||||
EV-to-EBITDA | -1.32 | |||||
EV-to-Forward-Revenue | 25781.12 | |||||
EV-to-FCF | -1.52 | |||||
| Price-to-Net-Current-Asset-Value | 2 | |||||
| Price-to-Net-Cash | 2.07 | |||||
Earnings Yield (Greenblatt) % | -75.76 | |||||
FCF Yield % | -30.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PMN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ProMIS Neurosciences Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -17.62 | ||
| Beta | -0.7855 | ||
| 3-Year Sharpe Ratio | -0.32 | ||
| 3-Year Sortino Ratio | -0.59 | ||
| Volatility % | 161.22 | ||
| 14-Day RSI | 53.8 | ||
| 14-Day ATR ($) | 0.632781 | ||
| 20-Day SMA ($) | 10.20225 | ||
| 12-1 Month Momentum % | -9.14 | ||
| 52-Week Range ($) | 6.27 - 39.75 | ||
| Shares Outstanding (Mil) | 8.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ProMIS Neurosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ProMIS Neurosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 43 days | ||
| H.C. Wainwright Neuro Perspectives Expert Summit | 2026-06-15 07:00 | 10.35 (-2.45%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 11:40 | 9.65 (-5.30%) | ||
| General meeting for 2026 | 2026-05-20 10:30 | 10.65 (+0.66%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 10.68 (+8.43%) | ||
| Annual report for 2025 | 2026-03-25 | 17.43 (+0.69%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 17.43 (+0.69%) | ||
| Guidance call for 2026 | 2026-02-11 09:30 | 14.29 (+7.93%) | ||
| 8(th) Annual Evercore Healthcare Conference | 2025-12-02 15:25 | 7.00 (+7.53%) |
Show
Entries
ProMIS Neurosciences Inc Frequently Asked Questions
What is ProMIS Neurosciences Inc(PMN)'s stock price today?
The current price of PMN is $13.39. The 52 week high of PMN is $39.75 and 52 week low is $6.27.
When is next earnings date of ProMIS Neurosciences Inc(PMN)?
The next earnings date of ProMIS Neurosciences Inc(PMN) is 2026-08-13 Est..
Does ProMIS Neurosciences Inc(PMN) pay dividends? If so, how much?
ProMIS Neurosciences Inc(PMN) does not pay dividend.
Guru Commentaries on NAS:PMN
No articles.
Press Release
Articles on ProMIS Neurosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers